GBT new logo.png
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
15. September 2022 18:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022,...
GBT new logo.png
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
08. August 2022 06:45 ET | Global Blood Therapeutics, Inc.; Pfizer, Inc.
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential...
GBT new logo.png
GBT Announces New Employment Inducement Grants
04. August 2022 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board...
GBT new logo.png
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
03. August 2022 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush...
GBT new logo.png
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
29. Juli 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on...
GBT new logo.png
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
26. Juli 2022 03:01 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA)...
GBT new logo.png
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
14. Juli 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in...
GBT new logo.png
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
29. Juni 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial...
GBT new logo.png
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
13. Juni 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results from the Sickle Cell Health Awareness, Perspectives and...
GBT new logo.png
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
06. Juni 2022 10:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced that it is...